ViewRay, Inc. Stock price

Equities

VRAYQ

US92672L1070

Advanced Medical Equipment & Technology

Delayed OTC Markets 09:39:35 2024-03-27 am EDT 5-day change 1st Jan Change
0.000001 USD 0.00% Intraday chart for ViewRay, Inc. -92.86% 0.00%
Sales 2021 70.12M Sales 2022 102M Capitalization 813M
Net income 2021 -110M Net income 2022 -107M EV / Sales 2021 11.8 x
Net cash position 2021 150M Net cash position 2022 49.56M EV / Sales 2022 7.47 x
P/E ratio 2021
-8.24 x
P/E ratio 2022
-7.54 x
Employees 295
Yield 2021 *
-
Yield 2022
-
Free-Float 91.76%
More Fundamentals * Assessed data
Dynamic Chart
1 month
0.00
Extreme 0
0.00
Current year
0.00
Extreme 0
0.00
1 year
0.00
Extreme 0
3.49
3 years
0.00
Extreme 0
8.25
5 years
0.00
Extreme 0
9.76
10 years
0.00
Extreme 0
13.21
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 18-12-31
Founder 53 03-12-31
Director of Finance/CFO 38 18-12-31
Members of the board TitleAgeSince
Director/Board Member 60 21-06-10
Director/Board Member 72 20-04-13
Director/Board Member 53 07-12-31
More insiders
Date Price Change Volume
24-03-27 0.000001 0.00% 8,000
24-03-22 0.000001 0.00% 3,107
24-03-21 0.000001 -92.86% 2,491
24-03-20 0.000014 +1,300.00% 74,200

Delayed Quote OTC Markets, March 27, 2024 at 09:39 am EDT

More quotes
ViewRay, Inc. is engaged in designing, manufacturing, and marketing the MRIdian MRI-Guided Radiation Therapy System. The MRIdian MR-Guided Radiation Therapy System integrates diagnostic MR imaging with radiation therapy delivery to enable on-table adaptive treatments with real-time tissue tracking and automatic beam gating. The MRIdian is comprised of three components, namely magnetic resonance imaging (MRI) system, radiation delivery system, and integrated treatment planning and delivery software. MRIdian employs MRI-based technology to provide real-time imaging that targets tumors from the surrounding soft tissue and other critical organs, both before and during radiation treatment delivery. MRIdian offers MR-guided imaging that provides tissue visualization compared to cone-beam computed tomography (CBCT), to enable contouring and reduced margins. The Company has installed approximately 56 MRIdian systems at hospitals, which are used to treat a variety of solid tumors.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock
  2. Equities
  3. Stock ViewRay, Inc. - OTC Markets